Immune checkpoint inhibitors as potential therapy for reverting T-cell exhaustion and reverting HIV latency in people living with HIV
JM Benito, C Restrepo, J García-Foncillas… - Frontiers in …, 2023 - frontiersin.org
The immune system of people living with HIV (PLWH) is persistently exposed to antigens
leading to systemic inflammation despite combination antiretroviral treatment (cART). This …
leading to systemic inflammation despite combination antiretroviral treatment (cART). This …
Has the Landscape of Immunotherapy for Prostate Cancer Changed? A Systematic Review and Post Hoc Analysis
MU Ashraf, U Farwa, M Siddiqa… - American journal of …, 2023 - journals.sagepub.com
Prostate cancer (PCa) is the second leading cause of cancer-causing death in the United
States. As the most common malignancy in men, it is pertinent to explore whether novel …
States. As the most common malignancy in men, it is pertinent to explore whether novel …
Examining exclusion criteria in advanced prostate cancer clinical trials: an assessment of recommendations from the American Society of Clinical Oncology and …
H Ebrahimi, DV Castro, MI Feng, SR Prajapati… - Clinical Genitourinary …, 2023 - Elsevier
Purpose Eligibility criteria illustrate the characteristics of the study population and promote
the safety of participants. However, overreliance on restrictive eligibility criteria may limit the …
the safety of participants. However, overreliance on restrictive eligibility criteria may limit the …
Prostate cancer in people with HIV
Prostate cancer is an increasingly common clinical issue for PWH. Lower than expected
incidence rates in the early ART-era may be increasing, and oncologic outcomes may also …
incidence rates in the early ART-era may be increasing, and oncologic outcomes may also …